A Market in Chaos The Market is in chaos. When this happens the market needs to be stopped from causing massive unwarranted harm to countries' economies, the firms and investors in the stock market. A healthy market does not drop over 2,500 points one day and then back up the same amount within the next few days. The current market is behaving like a drunk …

Stock Market Fluctuations and Volatility  Only history can remind us that what’s going on recently with the stock market is not new. Similar situations have taken place during the terms of every president since Ronald Reagan. Indeed, the same stock market's unexpected tumbling occurred during Reagan, Bush the father, Clinton, Bush the son, Obama and now Trump. As a matter of fact, history reminds us …

Treating and Preventing COVID-19 Treating COVID-19, Gilead Sciences With regard to treating patients with COVID-19 we believe the most expected product to be used during this virus' outbreak will be Gilead Sciences’ (GILD) product remdesivir. This product has reduced the severity of the coronavirus infection symptoms in animal testing and in a few . . . This content is for paid subscribers. Please click here to …

The Market Soared Being optimistic about the greatness of American scientific capability does not mean underestimating the coronavirus' ability to infect, devastate and threaten human lives. Today the market is rebounding from the fear that caused the stock market to plummet in this past week. The rebounding was strong enough to demonstrate that Americans trust their country’s scientific capabilities as well as their scientists’ and …

COVID-19 and the Stock Market The coronavirus that causes COVID-19 is the topic that swallowed all other topics this week. The virus is spreading to many countries around the world. Some media interpreted the CDC's warnings as being in direct conflict with the President while others showed understanding that the impact on the U.S. has so far been mild but the virus helped reveal the power …

Exelixis Announced Results from its CABOMETYX® Combination with Roche's TECENTRIQ® News announced by Exelixis (EXEL) about encouraging results from the combination of its product cabozantinib (CABOMETYX®) with Roche’s product atezolizumab (TECENTRIQ . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Gilead Stock Is UP Gilead Sciences' (GILD) provided its antiviral experimental drug remdesivir to physicians for a small number of patients infected with the 2019 novel coronavirus (2019-nCoV) as a possible emergency savior . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Vertex Beats Expectations in 2019 Vertex (VRTX) reported fourth-quarter and full-year 2019 financial results yesterday. The results beat analysts’ expectations about the last quarter and the whole year 2019. In the same report the firm’s full-year financial guidance promises a thrilling future for Vertex. The report indicated that the total GAAP and Non . . . This content is for paid subscribers. Please click here to …

Time to Remember Compugen The time has ripened for our readers and biotech investors to remember what we posted in the past years about Compugen (CGEN). The importance of the reminder is that the firm has taken a long time to bring its target discoveries and its targeted treatments into clinical trials whose preliminary results have demonstrated promise. Compugen

Forty Seven On December 21, 2018 Prohost picked Forty Seven (FTSV) at $16.95 adding it to its Portfolio of biotech firms with solid scientific and non-scientific fundamentals. Forty Seven develops novel checkpoint therapies to activate macrophages in the fight against cancer. The firm targets the CD47 pathway to engage macrophages in fighting tumors.  Macrophages function as . . . This content is for paid subscribers. …

Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. The new data were presented by the firm’s scientists during a late-breaking oral presentation at the 12thInternational Conference on Clinical Trials on . . . This content is for paid subscribers. …

Hepion Pharmaceuticals CRV431 Decreased Liver Fibrosis and Tumor Burden in Experimental Models EDISON, NJ / ACCESSWIRE / October 16, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

RegenxBio Interim Data from Phase I/IIa Trial of RGX-314 for Wet AMD RegenxBio (RGNX) announced interim data from the ongoing Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Here are the results as presented by the Company. The results were presented by Jeffrey S. Heier, M.D., Co-President and Director . . . This content is for paid subscribers. Please …

From Moderna  From the press release we learned that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Moderna (MRNA) investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. This is good news for

Palm Ebola Clinical Trial Stopped Early as Regeneron Product REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths TARRYTOWN, N.Y., Aug. 12, 2019,/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company was informed by study investigators that a randomized, controlled trial evaluating four investigational therapies for Ebola virus infection was stopped early because REGN-EB3 . . . This content is for paid …

Press Release Amgen Wins Patent Case On Enbrel® (etanercept) Court Upholds Validity of Patent Claims Directed to Enbrel Preliminary Injunction to Remain in Place THOUSAND OAKS, Calif., Aug. 9, 2019, /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

Nektar Press Release Nektar Therapeutics Results for Q2 of 2019 Nektar Therapeutics (Nasdaq: NKTR) reported its financial results for the second quarter ended June 30, 2019. Cash and investments in marketable securities at June 30, 2019 were $1.8 billion as compared to $1.9 billion at December . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

In This Column Every day thousands of press releases are issued about biotechnology and pharmaceutical firms. Only a few of these press releases have any impact, whether it be positive or negative, on the firms' that are the subject of these press releases. Prohost's Impacting News column will contain only those press releases that have news with a tremendous impact on the firms' that are …